The WHO revised diagnostic criteria for myeloprolative disorders: Clinical implication of the new criteria proposed by a recent expert panel meeting;Révision des critères diagnostiques de l'OMS pour les PV, TE et MPF: Proposition de nouveaux critères et analyse de la pertinence des précédents. Recommandations d'un groupe d'experts

Hematologie

Volumn 14, Issue 3, 2008, Pages 208-215

  Brière, Jean ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Bone marrow biopsy; JAK2V617F; Myeloproliferative disorders; PMFW515; Prefibrotic myelofibrosis; PV TE PMF; WHO diagnostic criteria

Indexed keywords

JANUS KINASE 2; THROMBOPOIETIN RECEPTOR;

BONE MARROW BIOPSY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; GENE MUTATION; GENETIC MARKER; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; POLYCYTHEMIA VERA; REVIEW; STANDARD; THROMBOCYTHEMIA; WORLD HEALTH ORGANIZATION;

EID: 49249138879     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia Vera. Nature 2005 ; 434 : 1 444-8.
2. Scott LM, Tong W, Levine RS, et al. JAK2 exon 12 mutations in Polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007 ; 356 : 459-68.
3. Pikman Y, Lee BH, Mercher T, et al. MPLW515L a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006 ; 3 : e270.
4. Imbert M, Pierre R, Thiele J, et al. Essential thrombocythaemia. In : Edited by :Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon : IARC press, 2001 : 39-41.
5. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia : a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003 ; 82 : 148-52.
6. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia : interobserver reliability and utility for identifying disease subtypes, prepublished online September 20, 2007 ; DOI 10.1182/Blood2007-05-091850.
7. Campbell PJ, Scott LM, Buck G, et al. United Kingdom Myeloproliferative Disorders Study Group ; Medical Research Council Adult Leukaemia Working Party ; Australasian Leukaemia and Lymphoma Group : Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status : a prospective study. Lancet 2005 ; 366 : 1945-53.
8. Michiels JJ, Berneman Z, van Bockstaele D, et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis ana bleeding complications and the molecular biology of essential thrombocythemia and polycythemia vera ; therapeutic implications. Seminars in thrombosis and hemostasis 2006 ; 32 : 174-207.
9. Villeval JL, James C, Pisani DF, et al. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. Semin Thromb Hemost 2006 ; 32 : 341-51.
10. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health. Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis : Recommendations from an ad hoc international expert panel. Blood 2007 ; 1 10 : 1092-7 ; (Epub 2007 May 8).
11. Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in the adults : expert panel on radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995 ; 89 : 748-56.
12. Tefferi A, Spivak JL. Polycythemia vera : scientific advances and current practice. Semin Hematol 2005 ; 42(4) : 206-20.
13. McMullin MF, Reilly JT, Campbell P, et al. on behalf of the National Cancer Research Institute, Myeloproliferative Disorder Subgroup, Kate Ryan, on behalf of the British Committee for Standards in Haematology. Amendment to the guideline for diagnosis and investigation of polycythaemia/ erythrocytosis. Br J Haematol 2007 ; 138 : 821-2.
14. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associted with marked thrombocytosis (RAR-T), another myeloproliferative condition characterised by JAK2 V617F mutation. Blood 2006 ; 108 : 2173-81.
15. Teofili L, Giona F, Martini M, et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007 ; 110 : 3384-6.
16. Campbell PJ. Green AR. Mechanisms of disease. The myeloproliferative disorders. N Engl J Med 2006 ; 255 : 2452-6.
17. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007 ; 6 : 550-66 ; (Epub 2007 Mar 24. Review).